Murphy MR, Ramadei A, Doymaz A, Varriano S, Natelson DM, Yu A, Aktas S, Mazzeo M, Mazzeo M, Zakusilo G et al..  2023.  Long non-coding RNA generated from CDKN1A gene by alternative polyadenylation regulates p21 expression during DNA damage response.. Nucleic Acids Res. 51(21):11911-11926.

Baksh SC, Finley LWS.  2022.  Metabolic diversity drives cancer cell invasion.. Nature. 605(7911):627-628.

Bu W, M Joyce G, Nguyen H, Banh DV, Aguilar F, Tariq Z, Yap MLan, Tsujimura Y, Gillespie RA, Tsybovsky Y et al..  2019.  Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.. Immunity. 50(5):1305-1316.e6.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.

Garcia-Bermudez J, Baudrier L, Bayraktar ECan, Shen Y, La K, Guarecuco R, Yucel B, Fiore D, Tavora B, Freinkman E et al..  2019.  Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death.. Nature. 567(7746):118-122.

Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzales V et al..  2018.  Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.. Cancer Discov. 8(8):1006-1025.

Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM et al..  2018.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.. Nat Immunol. 19(1):76-84.

Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Seelige R, Saddawi-Konefka R, Adams NM, Picarda G, Sun JC, Benedict CA, Bui JD.  2018.  Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection.. Sci Rep. 8(1):13670.

Guiberson NGuy Lewis, Pineda A, Abramov D, Kharel P, Carnazza KE, Wragg RT, Dittman JS, Burré J.  2018.  Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones.. Nat Commun. 9(1):3986.

Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM et al..  2018.  A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.. Nat Cell Biol. 20(12):1410-1420.

Belkacemi L, Atkins JL, Yang LU, Gadgil P, Sater AK, Chow DS, Bose RN, Zhang SXiaoliu.  2018.  Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly an Up-regulation of PEDF in Breast Cancer.. Anticancer Res. 38(2):623-646.

Feng M, Marjon KD, Zhu F, Weissman-Tsukamoto R, Levett A, Sullivan K, Kao KS, Markovic M, Bump PA, Jackson HM et al..  2018.  Programmed cell removal by calreticulin in tissue homeostasis and cancer.. Nat Commun. 9(1):3194.

Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AAri, Schietinger A, Scheinberg DA.  2018.  Rejection of immunogenic tumor clones is limited by clonal fraction.. Elife. 7

McBride MJ, Pulice JL, Beird HC, Ingram DR, D'Avino AR, Shern JF, Charville GW, Hornick JL, Nakayama RT, Garcia-Rivera EM et al..  2018.  The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.. Cancer Cell. 33(6):1128-1141.e7.

Rao TDharma, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J et al..  2017.  Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.. ACS Chem Biol. 12(8):2085-2096.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.  2017.  Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.. Oncotarget. 8(8):14017-14028.

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M et al..  2017.  Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.. Mol Pharm. 14(4):1047-1056.

Herting CJ, Chen Z, Pitter KL, Szulzewsky F, Kaffes I, Kaluzova M, Park JC, Cimino PJ, Brennan C, Wang B et al..  2017.  Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.. Glia. 65(12):1914-1926.

Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS et al..  2017.  HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase.. Sci Transl Med. 9(398)

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.  2017.  p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.. J Invest Dermatol. 137(10):2187-2196.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M et al..  2017.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.. Nature. 546(7658):431-435.

Liang H, Zheng Q-L, Fang P, Zhang J, Zhang T, Liu W, Guo M, Robinson CL, Chen S-B, Chen X-P et al..  2017.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.. Sci Rep. 7:40361.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M et al..  2017.  A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.. J Clin Invest. 127(7):2705-2718.